双次自体造血干细胞移植治疗恶性淋巴瘤的临床分析  

Clinical analysis of double autologous hematopoietic stem cell transplantation for malignant lymphoma

作　　者：刘焕凤[1] 张曦[1] 高蕾[1] 张诚[1] 高力[1] 李云龙[1] 刘学[1] 陈幸华[1] 

机构地区：[1]第三军医大学新桥医院血液科,重庆400037

出　　处：《重庆医学》2011年第30期3042-3043,共2页Chongqing medicine

摘　　要：目的分析双次自体造血干细胞移植(DAHSCT)治疗恶性淋巴瘤的临床疗效。方法对2006年1月至2009年4月12例恶性淋巴瘤患者在确诊后1年内进行第1次DAHSCT移植,以洛莫司汀(CCNU)+足叶乙甙+阿糖胞苷+环磷酰胺进行预处理,其中5例加用洛铂;以上患者在第1次DAHSCT术后4～6个月进行第2次DAHSCT,预处理方案为米托蒽醌+阿糖胞苷+环磷酰胺,其中有7例加入洛铂。结果所有患者经DAHSCT治疗后均获造血重建,第1次DAHSCT的造血重建速度快于第2次,经24～63个月随访,存活11例,死亡1例(死亡原因为重度感染),2年无病生存率为91.7%。结论 DAHSCT治疗恶性淋巴瘤相关死亡率低,无病生存率高,可用于恶性淋巴瘤的治疗。Objective To analyse the clinical efficacy of the double autologous hemopoietic stem cell transplantation （DAHSCT） for malignant lymphoma. Methods 12 patients with malignant lymphoma received the first AHSCT within 12 months after diagno- sis. They were pretreated with CCNU~ VP-16 Jr Ara-Cq-CTX, and five of them received CDDP additionally. All patients received the second AHSCT in 4 to 6 months after the first AHSCT. The patients were pretreated with MTZ＋Ara-C＋CTX,and seven of them received CDDP additionally. Results All patients obtained hemopoietic reconstitution,and the speed of first hemopoietic re- constitution was faster than that of the second. 11 cases of the 12 patients were survived during the analysis. The rate of 2-year dis- ease-free survival （DFS） was 91.7 %. Conclusion DAHSCT can be a safe and important treatment method for malignant lymphoma.

关 键 词：造血干细胞移植 淋巴瘤 治疗 

分 类 号：R733.1[医药卫生—肿瘤]